Medical School

Hematology, Oncology and Transplantation

Department of Medicine

David Potter, MD, PhD

UMP - Image - Size 3 - potter david

Academic Title

Associate Professor

Clinical Title

Hematologist / Oncologist

Specializations

  • Cancer
  • Breast Cancer
  • Hematology/Oncology

Practices

  • Breast Center

Education

Medical School
Johns Hopkins University, Baltimore, MD
Residency
Stanford University Medical Center, Stanford, CA

Administrative Contact

E: Barbara Porwit
P: (612) 624-5620
F: (612) 625-6919

 

Mailing Address

Division of Hematology, Oncology and Transplantation
420 Delaware Street SE, MMC 480
Minneapolis, MN 55455
 

Bio Statement

 After undergraduate studies in biology at M.I.T., Dr. Potter received M.D. and Ph.D. degrees from Johns Hopkins University. He trained in Internal Medicine at Stanford University Medical Center, and in Hematology and Oncology at Tufts-New England Medical Center. He performed post-doctoral studies at the M.I.T. Center for Cancer Research in the laboratory of Dr. Phillip Sharp. He was on the faculty at Tufts University, the Indiana University Cancer Center and moved to the University of Minnesota in 2006, where he is a member of the Breast Cancer Program at the Masonic Cancer Center.

 

Research Interests

  • Novel therapeutics for breast cancer

 

Leadership Roles
  • Member, American Society of Clinical Oncology
  • Member, American Society for Biochemistry and Molecular Biology
  • Member, American Association for Cancer Research
  • Translational Oncology Course Co-Leader, MSTP/MD, PhD Program Steering Committee
  • Breast ISC Team Leader, Cancer Biology Training Grant Steering Committee

 

Awards
  • Phi Beta Kappa
  • Excellence in Teaching Award, Tufts University School of Medicine (1999)
  • Walther Prize for Cancer Research, Walther Cancer Institute (2004)
  • Outstanding Clinical Teacher, Inidian University School of Medicine (2004)

 

Publications
  • Rodriguez M, Potter DA. CYP1A1 regulates breast cancer proliferation and survival. Mol Cancer Res. 2013 Jul;11(7):780-92. doi: 10.1158/1541-7786.MCR-12-0675. Epub 2013 Apr 10.Potter DA, Yee D, Guo Z, Rodriguez M. Should diabetic women with breast cancer have their own intervention studies? Endocr Relat Cancer 2012 Feb 13;19(1):C13-7.
  • Mitra R, Guo Z, Milani M, Mesaros C, Rodriguez M, Nguyen J, Luo X, Clarke D, Lamba J, Schuetz E, Donner DB, Puli N, Falck JR, Capdevila J, Gupta K, Blair IA, Potter DA. CYP3A4 Mediates Growth of Estrogen Receptor-positive Breast Cancer Cells in Part by Inducing Nuclear Translocation of Phospho-Stat3 through Biosynthesis of (+/-)-14,15-Epoxyeicosatrienoic Acid (EET). J Biol Chem. 2011 May 20;286(20):17543-59.
  • Srirangam A, Milani M, Mitra R, Guo Z, Rodriguez M, Kathuria H, Fukuda S, Rizzardi A, Schmechel S, Skalnik DG, Pelus LM, Potter DA. The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin. J Thorac Oncol. 2011 Apr;6(4):661-70.
  • Mitra R, Lee J, Jo J, Milani M, McClintick JN, Edenberg HJ, Kesler KA, Rieger KM, Badve S, Cummings OW, Mohiuddin A, Thomas DG, Luo X, Juliar BE, Li L, Mesaros C, Blair IA, Srirangam A, Kratzke RA, McDonald CJ, Kim J, Potter DA. Prediction of postoperative recurrence-free survival in non-small cell lung cancer by using an internationally validated gene expression model. Clin Cancer Res. 2011 May 1;17(9):2934-46.
  • Milani M, Jha G, Potter DA. Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women. Clin Med Ther. 2009 Mar 31;1:141-156.
  • Carpenter JS, Rawl S, Porter J, Schmidt K, Tornatta J, Ojewole F, Helft P, Potter DA, Sweeney C, Giesler RB. Oncology outpatient and provider responses to a computerized symptom assessment system. Oncol Nurs Forum. 2008; 35:661-669.
  • Srirangam A, Mitra R, Wang M, Gorski JC, Badve S, Baldridge LA, Hamilton J, Kishimoto H, Hawes J, Li L, Blum JS, Donner DB, Sledge GW, Nakshatri H, Potter DA. Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer. Clin. Cancer Res. 2006; 12: 1883-1896.
  • Zhang B, Srirangam A, Potter DA, Roman A. 2005. HPV16 E5 protein disrupts the c-Cbl-EGFR interaction and EGFR ubiquitination in human foreskin keratinocytes. Oncogene 2005; 24:2585-2588.
  • Henley JD, Summerlin DJ, Potter DA, Timmerman RD, Tomich CE. Intraoral mucin-rich salivary duct carcinoma. Histopathology 2005; 47(4):436-437.
  • Narayanasamy V, Mukhopadhyay S, Palakal M, Potter DA. TransMiner: Mining transitive associations among biological objects from text. Journal of Biomedical Science 2004; 11:864-873.
  • Glading A, Bodnar R, Reynolds IJ , Shiraha H, Satish L, Potter DA, Blair HC, Wells A. EGF activates m-calpain (calpain 2), at least in part, by ERK-mediated phosphorylation. Mol. Cell. Biol. 2004; 24: 2499-2512.

 

  • ©2014 Regents of the University of Minnesota. All rights reserved.
  • The University of Minnesota is an equal opportunity educator and employer
  • Last modified on April 2, 2014